Biotech News

Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026

Amarin Corporation (AMRN)Amarin CorporationCompany update

Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted new clinical data evaluating lipoprotein(a) [Lp(a)] and other apolipoprotein B (apoB) containing lipoproteins as predictors of major adverse cardiovascular events (MACE), as well as new mechanistic findings examining the effects of eicosapentaenoic acid (EPA) on Lp(a) oxidation and related inflammatory and oxidative stress pathways. The data were presented at the American Heart Association (AHA) Scientific Sessions 2026 this weekend in Chicago, Illinois.

Related news

Amarin Corporation

Cardiovascular Therapeutics Company Amarin is a cardiovascular-focused pharmaceutical company built around prescription icosapent ethyl. Its commercial strategy combines a continuing U.S. presence with regional partners responsible for regulatory, market-access, and sales activities internationally. VASCEPA and VAZKEPA The product is...

Recent company news

Stock data

Close
11.26 USD
Market cap
303.42M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States